Trial Profile
Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 28 Jan 2022 Status changed from recruiting to completed.
- 29 Aug 2018 Protocol amended due to change in design keywords, planned end dates, planned patient number according to ClinicalTrials.gov record.
- 29 Aug 2018 Planned number of patients changed from 350 to 450.